Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more

Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

240.7M

52 Wk Range

$1.61 - $9.88

Previous Close

$3.76

Open

$3.75

Volume

765,895

Day Range

$3.65 - $4.01

Enterprise Value

88.08M

Cash

157.5M

Avg Qtr Burn

-21.72M

Insider Ownership

1.43%

Institutional Own.

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.